Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 31 entries
Sorted by: Best Match Show Resources per page
Eulerian formulation of elastic rods.

Proceedings. Mathematical, physical, and engineering sciences

Huynen A, Detournay E, Denoël V.
PMID: 27436960
Proc Math Phys Eng Sci. 2016 Jun;472(2190):20150547. doi: 10.1098/rspa.2015.0547.

In numerous biological, medical and engineering applications, elastic rods are constrained to deform inside or around tube-like surfaces. To solve efficiently this class of problems, the equations governing the deflection of elastic rods are reformulated within the Eulerian framework...

Cite
Huynen A, Detournay E, Denoël V. Eulerian formulation of elastic rods. Proc Math Phys Eng Sci. 2016;472(2190):20150547doi: 10.1098/rspa.2015.0547.
Huynen, A., Detournay, E., & Denoël, V. (2016). Eulerian formulation of elastic rods. Proceedings. Mathematical, physical, and engineering sciences, 472(2190), 20150547. https://doi.org/10.1098/rspa.2015.0547
Huynen, Alexandre, et al. "Eulerian formulation of elastic rods." Proceedings. Mathematical, physical, and engineering sciences vol. 472,2190 (2016): 20150547. doi: https://doi.org/10.1098/rspa.2015.0547
Huynen A, Detournay E, Denoël V. Eulerian formulation of elastic rods. Proc Math Phys Eng Sci. 2016 Jun;472(2190):20150547. doi: 10.1098/rspa.2015.0547. PMID: 27436960; PMCID: PMC4950185.
Copy Download .nbib Format: NLM
Inner mechanics of three-dimensional black holes.

Physical review letters

Detournay S.
PMID: 22861835
Phys Rev Lett. 2012 Jul 20;109(3):031101. doi: 10.1103/PhysRevLett.109.031101. Epub 2012 Jul 17.

We investigate properties of the inner horizons of certain black holes in higher-derivative three-dimensional gravity theories. We focus on Bañados-Teitelboim-Zanelli and spacelike warped anti-de Sitter black holes, as well as on asymptotically warped de Sitter solutions exhibiting both a...

Cite
Detournay S. Inner mechanics of three-dimensional black holes. Phys Rev Lett. 2012;109(3):031101doi: 10.1103/PhysRevLett.109.031101.
Detournay, S. (2012). Inner mechanics of three-dimensional black holes. Physical review letters, 109(3), 031101. https://doi.org/10.1103/PhysRevLett.109.031101
Detournay, Stéphane. "Inner mechanics of three-dimensional black holes." Physical review letters vol. 109,3 (2012): 031101. doi: https://doi.org/10.1103/PhysRevLett.109.031101
Detournay S. Inner mechanics of three-dimensional black holes. Phys Rev Lett. 2012 Jul 20;109(3):031101. doi: 10.1103/PhysRevLett.109.031101. Epub 2012 Jul 17. PMID: 22861835.
Copy Download .nbib Format: NLM
Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study.

Diabetes & metabolism

Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E.
PMID: 34813929
Diabetes Metab. 2021 Nov 21;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21.

Type 1 diabetes mellitus (T1DM) is associated with a high risk of cardiovascular (CV) complications, even after controlling for traditional CV risk factors. Therefore, determinants of the residual increased CV morbidity and mortality remain to be discovered. This prospective...

Cite
Riveline JP, Vergés B, Detournay B, et al. Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes Metab. 2021;48(3):101306doi: 10.1016/j.diabet.2021.101306.
Riveline, J. P., Vergés, B., Detournay, B., Picard, S., Benhamou, P. Y., Bismuth, E., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., Sola-Gazagnes, A., Bonnefond, A., Clavel, S., Velayoudom, F. L., Beltrand, J., Hanaire, H., Fontaine, P., Thivolet, C., Servy, H., Tubiana, S., Lion, S., Gautier, J. F., Larger, E., Vicaut, E., Sablone, L., Fagherazzi, G., & Cosson, E. (2021). Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes & metabolism, 48(3), 101306. https://doi.org/10.1016/j.diabet.2021.101306
Riveline, J P, et al. "Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study." Diabetes & metabolism vol. 48,3 (2021): 101306. doi: https://doi.org/10.1016/j.diabet.2021.101306
Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E. Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes Metab. 2021 Nov 21;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21. PMID: 34813929.
Copy Download .nbib Format: NLM
Flat-space chiral gravity.

Physical review letters

Bagchi A, Detournay S, Grumiller D.
PMID: 23102291
Phys Rev Lett. 2012 Oct 12;109(15):151301. doi: 10.1103/PhysRevLett.109.151301. Epub 2012 Oct 09.

We provide the first evidence for a holographic correspondence between a gravitational theory in flat space and a specific unitary field theory in one dimension lower. The gravitational theory is a flat-space limit of topologically massive gravity in three...

Cite
Bagchi A, Detournay S, Grumiller D. Flat-space chiral gravity. Phys Rev Lett. 2012;109(15):151301doi: 10.1103/PhysRevLett.109.151301.
Bagchi, A., Detournay, S., & Grumiller, D. (2012). Flat-space chiral gravity. Physical review letters, 109(15), 151301. https://doi.org/10.1103/PhysRevLett.109.151301
Bagchi, Arjun, et al. "Flat-space chiral gravity." Physical review letters vol. 109,15 (2012): 151301. doi: https://doi.org/10.1103/PhysRevLett.109.151301
Bagchi A, Detournay S, Grumiller D. Flat-space chiral gravity. Phys Rev Lett. 2012 Oct 12;109(15):151301. doi: 10.1103/PhysRevLett.109.151301. Epub 2012 Oct 09. PMID: 23102291.
Copy Download .nbib Format: NLM
Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France.

The European journal of health economics : HEPAC : health economics in prevention and care

Detournay B, Pribil C, Jourdanne C, Price M.
PMID: 15609139
Eur J Health Econ. 2002;3(3):149-55. doi: 10.1007/s10198-002-0111-z.

A budget impact model was used to estimate the effect of introducing inhaled salmeterol/fluticasone propionate combination on asthma drug-related costs in France. The model is based on disease prevalence, drug use, drug acquisition cost and sales forecasting data specific...

Cite
Detournay B, Pribil C, Jourdanne C, et al. Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France. Eur J Health Econ. 2002;3(3):149-55doi: 10.1007/s10198-002-0111-z.
Detournay, B., Pribil, C., Jourdanne, C., & Price, M. (2002). Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France. The European journal of health economics : HEPAC : health economics in prevention and care, 3(3), 149-55. https://doi.org/10.1007/s10198-002-0111-z
Detournay, B, et al. "Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France." The European journal of health economics : HEPAC : health economics in prevention and care vol. 3,3 (2002): 149-55. doi: https://doi.org/10.1007/s10198-002-0111-z
Detournay B, Pribil C, Jourdanne C, Price M. Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France. Eur J Health Econ. 2002;3(3):149-55. doi: 10.1007/s10198-002-0111-z. PMID: 15609139.
Copy Download .nbib Format: NLM
Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Pechevis M, Detournay B, Pribil C, Fagnani F, Chalanson G.
PMID: 16464198
Value Health. 2000 Nov-Dec;3(6):389-96. doi: 10.1046/j.1524-4733.2000.36008.x.

OBJECTIVES: This paper presents an economic evaluation of a strategy of thromboprophylaxis in acutely ill medical patients with enoxaparin 40 mg vs. no intervention in the context of the French Health System.METHODS: The evaluation used a decision-analysis model to...

Cite
Pechevis M, Detournay B, Pribil C, et al. Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value Health. 2000;3(6):389-96doi: 10.1046/j.1524-4733.2000.36008.x.
Pechevis, M., Detournay, B., Pribil, C., Fagnani, F., & Chalanson, G. (2000). Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 3(6), 389-96. https://doi.org/10.1046/j.1524-4733.2000.36008.x
Pechevis, M, et al. "Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 3,6 (2000): 389-96. doi: https://doi.org/10.1046/j.1524-4733.2000.36008.x
Pechevis M, Detournay B, Pribil C, Fagnani F, Chalanson G. Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value Health. 2000 Nov-Dec;3(6):389-96. doi: 10.1046/j.1524-4733.2000.36008.x. PMID: 16464198.
Copy Download .nbib Format: NLM
Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Roussel R, Charbonnel B, Behar M, Gourmelen J, Emery C, Detournay B.
PMID: 27421274
Diabetes Ther. 2016 Sep;7(3):537-49. doi: 10.1007/s13300-016-0185-8. Epub 2016 Jul 15.

INTRODUCTION: The objective of this study was to document the initiation of insulin therapy in patients with type 2 diabetes mellitus (T2DM) and its maintenance as a function of time after initiation in a French nationwide representative cohort.METHODS: A...

Cite
Roussel R, Charbonnel B, Behar M, et al. Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. Diabetes Ther. 2016;7(3):537-49doi: 10.1007/s13300-016-0185-8.
Roussel, R., Charbonnel, B., Behar, M., Gourmelen, J., Emery, C., & Detournay, B. (2016). Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 7(3), 537-49. https://doi.org/10.1007/s13300-016-0185-8
Roussel, Ronan, et al. "Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 7,3 (2016): 537-49. doi: https://doi.org/10.1007/s13300-016-0185-8
Roussel R, Charbonnel B, Behar M, Gourmelen J, Emery C, Detournay B. Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. Diabetes Ther. 2016 Sep;7(3):537-49. doi: 10.1007/s13300-016-0185-8. Epub 2016 Jul 15. PMID: 27421274; PMCID: PMC5014791.
Copy Download .nbib Format: NLM
Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France.

PharmacoEconomics - open

Detournay B, Boultif Z, Bahloul A, Jeanbat V, Robert J.
PMID: 33215332
Pharmacoecon Open. 2021 Jun;5(2):211-219. doi: 10.1007/s41669-020-00237-4. Epub 2020 Nov 20.

OBJECTIVE: Our objectives were to describe the basal insulin treatment regimens most widely used in a real-world setting in France and to estimate the associated treatment costs in people with type 2 diabetes mellitus (T2DM).METHODS: A cross-sectional observational study...

Cite
Detournay B, Boultif Z, Bahloul A, et al. Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France. Pharmacoecon Open. 2020;5(2):211-219doi: 10.1007/s41669-020-00237-4.
Detournay, B., Boultif, Z., Bahloul, A., Jeanbat, V., & Robert, J. (2021). Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France. PharmacoEconomics - open, 5(2), 211-219. https://doi.org/10.1007/s41669-020-00237-4
Detournay, Bruno, et al. "Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France." PharmacoEconomics - open vol. 5,2 (2021): 211-219. doi: https://doi.org/10.1007/s41669-020-00237-4
Detournay B, Boultif Z, Bahloul A, Jeanbat V, Robert J. Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France. Pharmacoecon Open. 2021 Jun;5(2):211-219. doi: 10.1007/s41669-020-00237-4. Epub 2020 Nov 20. PMID: 33215332; PMCID: PMC8160062.
Copy Download .nbib Format: NLM
Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study.

Diabetes & metabolism

Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E.
PMID: 34813929
Diabetes Metab. 2021 Nov 21;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21.

Type 1 diabetes mellitus (T1DM) is associated with a high risk of cardiovascular (CV) complications, even after controlling for traditional CV risk factors. Therefore, determinants of the residual increased CV morbidity and mortality remain to be discovered. This prospective...

Cite
Riveline JP, Vergés B, Detournay B, et al. Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes Metab. 2021;48(3):101306doi: 10.1016/j.diabet.2021.101306.
Riveline, J. P., Vergés, B., Detournay, B., Picard, S., Benhamou, P. Y., Bismuth, E., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., Sola-Gazagnes, A., Bonnefond, A., Clavel, S., Velayoudom, F. L., Beltrand, J., Hanaire, H., Fontaine, P., Thivolet, C., Servy, H., Tubiana, S., Lion, S., Gautier, J. F., Larger, E., Vicaut, E., Sablone, L., Fagherazzi, G., & Cosson, E. (2021). Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes & metabolism, 48(3), 101306. https://doi.org/10.1016/j.diabet.2021.101306
Riveline, J P, et al. "Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study." Diabetes & metabolism vol. 48,3 (2021): 101306. doi: https://doi.org/10.1016/j.diabet.2021.101306
Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E. Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes Metab. 2021 Nov 21;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21. PMID: 34813929.
Copy Download .nbib Format: NLM
Holography of 3D flat cosmological horizons.

Physical review letters

Bagchi A, Detournay S, Fareghbal R, Simón J.
PMID: 25166977
Phys Rev Lett. 2013 Apr 05;110(14):141302. doi: 10.1103/PhysRevLett.110.141302. Epub 2013 Apr 02.

We provide a first derivation of the Bekenstein-Hawking entropy of 3D flat cosmological horizons in terms of the counting of states in a dual field theory. These horizons appear in the flat limit of nonextremal rotating Banados-Teitleboim-Zanelli black holes...

Cite
Bagchi A, Detournay S, Fareghbal R, et al. Holography of 3D flat cosmological horizons. Phys Rev Lett. 2013;110(14):141302doi: 10.1103/PhysRevLett.110.141302.
Bagchi, A., Detournay, S., Fareghbal, R., & Simón, J. (2013). Holography of 3D flat cosmological horizons. Physical review letters, 110(14), 141302. https://doi.org/10.1103/PhysRevLett.110.141302
Bagchi, Arjun, et al. "Holography of 3D flat cosmological horizons." Physical review letters vol. 110,14 (2013): 141302. doi: https://doi.org/10.1103/PhysRevLett.110.141302
Bagchi A, Detournay S, Fareghbal R, Simón J. Holography of 3D flat cosmological horizons. Phys Rev Lett. 2013 Apr 05;110(14):141302. doi: 10.1103/PhysRevLett.110.141302. Epub 2013 Apr 02. PMID: 25166977.
Copy Download .nbib Format: NLM
[Economic evaluation in healthcare].

Medecine sciences : M/S

Detournay B.
PMID: 24939547
Med Sci (Paris). 2014 May;30(5):584-7. doi: 10.1051/medsci/20143005023. Epub 2014 Jun 13.

Economics was only recently considered as a dimension of health technology assessment in France. Yet there are always limits in resources that we collectively agree to devote to health. A comparative "economic" appraisal is therefore needed to guide health...

Cite
Detournay B. L'évaluation économique dans le champ de la santé [Economic evaluation in healthcare]. Med Sci (Paris). 2014;30(5):584-7doi: 10.1051/medsci/20143005023.
Detournay, B. (2014). L'évaluation économique dans le champ de la santé [Economic evaluation in healthcare]. Medecine sciences : M/S, 30(5), 584-7. https://doi.org/10.1051/medsci/20143005023
Detournay, Bruno. "L'évaluation économique dans le champ de la santé" [Economic evaluation in healthcare]. Medecine sciences : M/S vol. 30,5 (2014): 584-7. doi: https://doi.org/10.1051/medsci/20143005023
Detournay B. L'évaluation économique dans le champ de la santé [Economic evaluation in healthcare]. Med Sci (Paris). 2014 May;30(5):584-7. doi: 10.1051/medsci/20143005023. Epub 2014 Jun 13. French. PMID: 24939547.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Dervaux B, Baseilhac E, Fagon JY, Biot C, Blachier C, Braun E, Debroucker F, Detournay B, Ferretti C, Granger M, Jouan-Flahault C, Lussier MD, Meyer A, Muller S, Pigeon M, De Sahb R, Sannié T, Sapède C, Vray M.
PMID: 27393226
Therapie. 2014 Jul-Aug;69(4):323-30. doi: 10.2515/therapie/2014046.

No abstract available.

Cite
Dervaux B, Baseilhac E, Fagon JY. Évaluation médico-économique des produits de santé. Méthodologie pour la définition d'un impact significatif sur les dépenses de l'Assurance maladie et choix des référentiels pour l'interprétation des résultats. [Not Available]. Therapie. 2014;69(4):323-30doi: 10.2515/therapie/2014046.
Dervaux, B., Baseilhac, E., Fagon, J. Y., Biot, C., Blachier, C., Braun, E., Debroucker, F., Detournay, B., Ferretti, C., Granger, M., Jouan-Flahault, C., Lussier, M. D., Meyer, A., Muller, S., Pigeon, M., De Sahb, R., Sannié, T., Sapède, C., & Vray, M. (2014). Évaluation médico-économique des produits de santé. Méthodologie pour la définition d'un impact significatif sur les dépenses de l'Assurance maladie et choix des référentiels pour l'interprétation des résultats. [Not Available]. Therapie, 69(4), 323-30. https://doi.org/10.2515/therapie/2014046
Dervaux, Benoît, et al. "Évaluation médico-économique des produits de santé. Méthodologie pour la définition d'un impact significatif sur les dépenses de l'Assurance maladie et choix des référentiels pour l'interprétation des résultats." [Not Available]. Therapie vol. 69,4 (2014): 323-30. doi: https://doi.org/10.2515/therapie/2014046
Dervaux B, Baseilhac E, Fagon JY, Biot C, Blachier C, Braun E, Debroucker F, Detournay B, Ferretti C, Granger M, Jouan-Flahault C, Lussier MD, Meyer A, Muller S, Pigeon M, De Sahb R, Sannié T, Sapède C, Vray M. Évaluation médico-économique des produits de santé. Méthodologie pour la définition d'un impact significatif sur les dépenses de l'Assurance maladie et choix des référentiels pour l'interprétation des résultats. [Not Available]. Therapie. 2014 Jul-Aug;69(4):323-30. doi: 10.2515/therapie/2014046. French. PMID: 27393226.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 31 entries